Morrison & Foerster LLP partner David C. Doyle has successfully fought for generic drug companies’ access to markets years before competitors’ exclusivity runs out, including Sandoz Inc.’s bid to invalidate Teva Pharmaceutical USA Inc.’s patents for its $3 billion a year Copaxone drug, netting him a spot on Law360’s list of Life Sciences MVPs.
Doyle, who leads Morrison’s Abbreviated New Drug Application litigation group from the firm’s San Diego office, says he was drawn to science law because of the added complexity of the inner workings of living systems, in addition to the intricacies of the law.
Originally published in Law360 on December 13, 2013.
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.